The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with
simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart
disease, non-hemorrhagic stroke and the need for revascularization procedures in patients
with chronic kidney disease (CKD). It also aimed to assess whether lowering LDL cholesterol
reduced the rate of loss of renal function in people with CKD who had not commenced dialysis
treatment.
Phase:
Phase 4
Details
Lead Sponsor:
University of Oxford
Collaborators:
British Heart Foundation Medical Research Council Merck Sharp & Dohme Corp. National Health and Medical Research Council, Australia Schering-Plough